#391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategy

8 min

•May 11, 202623 days ago

Summary

Peter Attia explores colorectal cancer screening, explaining why CRC is the most preventable cancer despite being the second leading cause of cancer death in the US. The episode covers CRC biology, the rise of early-onset cases, colonoscopy as both screening and prevention tool, and emerging non-invasive screening alternatives.

Insights

68% of colorectal cancer deaths could be prevented with current screening protocols, yet most occur because people never get screened—suggesting a massive gap between available prevention and utilization
Colonoscopy is uniquely valuable compared to other cancer screenings because it can both detect AND remove precancerous lesions before they become cancer, not just detect existing disease
CRC follows a well-characterized, slow progression from normal tissue to benign polyp to precancerous polyp to malignancy, typically taking a decade or more—providing an extended intervention window
Early-onset colorectal cancer in younger adults is rising, challenging traditional screening age recommendations and requiring personalized screening strategies
Non-invasive screening options (stool-based and blood-based tests) have significant limitations compared to colonoscopy and should be understood within a comprehensive screening strategy

Trends

Rising incidence of early-onset colorectal cancer in younger adults shifting screening paradigmsGrowing adoption of non-invasive screening alternatives (Cologuard, blood tests) despite limitations versus colonoscopyShift toward personalized, risk-stratified screening intervals rather than one-size-fits-all protocolsIncreased focus on screening quality metrics and ensuring high-quality colonoscopy proceduresGap between preventable cancer deaths and actual screening rates indicating public health communication opportunityMovement toward earlier screening initiation ages based on emerging early-onset CRC data

Topics

Colorectal cancer screening protocols and intervalsColonoscopy procedure quality and preparationEarly-onset colorectal cancer epidemiologyPrecancerous polyp detection and removalNon-invasive screening alternatives (stool-based and blood-based tests)Colorectal cancer prevention strategiesCancer screening risk-benefit analysisPersonalized screening strategiesColorectal cancer mortality statisticsColonoscopy versus alternative screening modalitiesCologuard and emerging biomarker testsScreening age recommendationsAdenoma detection ratesPatient compliance with cancer screeningColorectal cancer pathophysiology

Companies

American Cancer Society

Cited for 2024 colorectal cancer death projections and epidemiological data on CRC mortality

CDC

Referenced for 2020 estimate that 68% of colorectal cancer deaths may be prevented with screening

People

Peter Attia

Host and primary speaker discussing colorectal cancer screening comprehensively

Quotes

"CRC is arguably the most preventable cancer we know of. And the reason for this is that CRC follows a well characterized, slow progression from completely normal tissue to a benign polyp to a precancerous polyp to frank malignancy."

Peter Attia•Early in episode

"A colonoscopy can not only detect cancer, but it can also remove the precancerous lesion in the first place. No other common cancer screening test can make that claim."

Peter Attia•Mid-episode

"A 2020 CDC estimate claims that 68% of colorectal cancer deaths may be prevented with screening even at the traditional recommended intervals. Again, that statistic should stop you cold."

Peter Attia•Early-mid episode

"We're talking about a cancer that in most cases gives us a decades long window to intervene and we're still losing nearly 70% of people out of that 55,000 deaths a year because they never walked through the front door to get a colonoscopy."

Peter Attia•Mid-episode

Full Transcript

Hey everyone, welcome to a sneak peek episode of the Drive podcast. I'm your host, Peter Atia. At the end of this short episode, I'll explain how you can access the episodes in full along with a ton of other membership benefits we've created. Or you can learn more now by going to peteratea.md.com forward slash subscribe. So without further delay, here's today's sneak peek of the episode. Welcome to a new episode of the Drive. In today's episode, I'm diving into colorectal cancer screening. Why colorectal cancer is one of the most preventable cancers we know of and why getting screening right matters so much. In this episode, I'm going to discuss many things, but among them how colorectal cancer develops. Why colonoscopy is uniquely valuable as both a screening and preventive tool, the troubling rise in early onset colorectal cancer, and how to think clearly about the growing menu of noninvasive screening options and their limitations. If you're not a subscriber, you'll only be able to listen to a sneak peek here. So without further delay, I hope you'll enjoy today's episode of the Drive. So colorectal cancer, or CRC as we'll abbreviate it, is the second leading cause of cancer death in the United States. And it's projected to be responsible for roughly 55,000 deaths this year, according to the American Cancer Society. That puts it behind only lung cancer as far as cancer mortality. And yet, unlike many other cancers, CRC is arguably the most preventable cancer we know of. And the reason for this is that CRC follows a well characterized, slow progression from completely normal tissue to a benign polyp to a precancerous polyp to frank malignancy. And that progression almost always takes years, often a decade or more. And because the colon is a hollow organ and sits outside the body as crazy as that sounds, we can directly access and visualize it. We have the ability to not only detect those precancerous lesions, but also remove them before they ever become cancer. So no other common cancer screening test can make that claim. A mammogram can detect breast cancer, a low dose CT scan can detect lung cancer, but neither of those are able to look directly at the cancer. And so a colonoscopy can not only do that, but it can also remove the precancerous lesion in the first place. And yet, a 2020 CDC estimate claims that 68% of colorectal cancer deaths may be prevented with screening even at the traditional recommended intervals. Again, that statistic should stop you cold. We're talking about a cancer that in most cases gives us a decades long window to intervene and we're still losing nearly 70% of people out of that 55,000 deaths a year because they never walked through the front door to get a colonoscopy. Even more, I would argue that this number could be closer to 100%, i.e. 100% reduction in colorectal cancer death with more aggressive screening protocols, including starting earlier and screening more often. So today I want to cover this topic comprehensively. We'll start with the basic biology of colorectal cancer and why it's uniquely suited to screening. Then we'll talk about the rise of early onset colorectal cancer in younger adults. From there, we'll go into the colonoscopy itself, how to prepare for one, how to ensure you're getting a high quality exam, and how to think about screening intervals. We'll discuss real risks and trade-offs and finally we'll walk through the growing landscape of non-invasive screening alternatives, both stool-based tests and blood-based tests, and talk about what they can and can't do. The goal here is to leave you with a very clear, practical picture of colorectal cancer screening, whether you're 35 and wondering when to start or 55 and wondering when your colaguard test is good enough. Thank you for listening to today's sneak peek episode of The Drive. If you're interested in hearing the complete version, you'll want to become a premium member. It's extremely important to me to provide all of this content without relying on paid ads. To do this, our work is made entirely possible by our members and in return, we offer exclusive member-only content and benefits above and beyond what is available for free. So if you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription. Premium membership includes several benefits. First, comprehensive podcast show notes that detail every topic, paper, person, and thing that we discuss in each episode. And the word on the street is, nobody's show notes rival ours. Second, monthly ask me anything or AMA episodes. These episodes are comprised of detailed responses to subscriber questions typically focused on a single topic and are designed to offer a great deal of clarity and detail on topics of special interest to our members. You'll also get access to the show notes for these episodes, of course. Third, delivery of our premium newsletter, which is put together by our dedicated team of research analysts. This newsletter covers a wide range of topics related to longevity and provides much more detail than our free weekly newsletter. Fourth, access to our private podcast feed that provides you with access to every episode, including AMAs, Sans the Spiel you're listening to now, and in your regular podcast feed. Fifth, the qualities, an additional member only podcast we put together that serves as a highlight reel featuring the best excerpts from previous episodes of the drive. This is a great way to catch up on previous episodes without having to go back and listen to each one of them. And finally, other benefits that are added along the way. If you want to learn more and access these member only benefits, you can head over to peteratea.com. You can also find me on YouTube, Instagram and Twitter, all with the handle Peter AteaMD. You can also leave us a review on Apple podcasts or whatever podcast player you use. This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis or treatment. Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their health care professionals for any such conditions. Finally, I take all conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit peteratea.com forward slash about where I keep an up to date and active list of all disclosures.